Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results
MENLO PARK, Calif., Feb. 18, 2026 – Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2025, after the market closes on Wednesday, March 4, 2026.
Conference Call Details
The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in participating can access a live and archived webcast of the event at www.sightsciences.com, in the News & Events section of the Investors page. The webcast will be available for replay for at least 90 days following the event.
About Sight Sciences
Sight Sciences is focused on developing and commercializing innovative, interventional technologies to transform eye care and improve patient outcomes. The company utilizes minimally invasive or non-invasive approaches to address the root causes of prevalent eye diseases, aiming to create more effective treatment options.
Key products include:
- OMNI® Surgical System and OMNI® Edge Surgical System: Implant-free, minimally invasive glaucoma surgery technologies approved in the United States to reduce intraocular pressure in patients with primary open-angle glaucoma. The OMNI Surgical System is also CE Marked for catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in patients with open-angle glaucoma.
- SION® Surgical System: A bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
- TearCare® System: 510(k) cleared in the United States for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), facilitating the clearance of gland obstructions.
Glaucoma is a leading cause of irreversible blindness worldwide.
Investor and Media Contact Information
Investor contact:
Philip Taylor
Gilmartin Group
Investor.Relations@Sightsciences.com
415.937.5406
Media contact:
pr@SightSciences.com
© 2026 Sight Sciences. All rights reserved.